Elucid Bioimaging key facts
as of Oct 2026- Developer of an imaging system designed to improve patient outcomes at a reduced cost by applying artificial intelligence to vascular diagnostic imaging.
- Elucid Bioimaging is valued at approximately $288.0M as of Oct 2026, set at its later-stage round, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $163.2M across 3 recorded rounds; the latest was Early Stage VC ($36.5M) in Oct 2025.
- Notable investors include Sand Hill Angels, IAG Capital Partners, University of Michigan Endowment, Elevage Medical Technologies, Angel Physicians Fund — 24 tracked in total.
- Elucid Bioimaging has filed 2 Form Ds with the SEC since 2013, most recently Nov 2023 ($79.0M sold to 13 investors).
- Status: Privately Held (backing).
Valued at $288.0M at its later-stage round, Oct 2025. Nothing has traded since.
- ·The complete investor list: 24 names
- ·Watch Elucid Bioimaging: the Monday email on marks, rounds and moves
Elucid Bioimaging funding rounds
3 roundsWho backs Elucid Bioimaging
24+Elucid Bioimaging valuation
Elucid Bioimaging was valued at $288 million at its later-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Elucid Bioimaging raised?
Elucid Bioimaging has raised $163 million across 3 recorded rounds since 2013. The largest was a $79 million later-stage round in Oct 2023; the most recent was a $36.5 million early-stage round in Oct 2025.
Elucid Bioimaging has filed 2 Form Ds with the SEC since 2013, most recently in Nov 2023 ($79 million sold to 13 investors).
Elucid Bioimaging investors
24 investors are on record for Elucid Bioimaging, including Sand Hill Angels, IAG Capital Partners, University of Michigan Endowment and Elevage Medical Technologies. The early-stage round in Oct 2025 drew 9 investors.
About Elucid Bioimaging
Developer of an imaging system designed to improve patient outcomes at a reduced cost by applying artificial intelligence to vascular diagnostic imaging. The company's system objectively quantifies the extent and stability of arterial plaque and offers an economically efficient and non-invasive method for capturing patient health information, enabling cardiovascular pathologists to enhance their patient care and provide comprehensive and accurate clinical insights.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Employees
- 127
- Website
- elucid.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.